Reference Detail

Ref Type

PMID

Authors

Abdul Rafeh Naqash, Arjun Mittra, Geraldine Helen O'Sullivan Coyne, Li Chen, Biswajit Das, Shivaani Kummar, Khanh T Do, Ting-Chia Chang, Ashley Bruns, Lamin Juwara, Brandon Miller, Robert J. Kinders, Ralph E. Parchment, Larry V Rubinstein, Jiuping Jay Ji, Deborah Wilsker, Angie B Dull, James H. Doroshow, Alice P. Chen, Naoko Takebe

Title

Tumor genomic analysis for biomarker identification in a phase I trial of the Wee 1 inhibitor adavosertib (AZD1775).

Journal	Vol	Issue	Date	Pages	Journal Short Title

URL

https://meetinglibrary.asco.org/record/188230/abstract

Abstract Text

J Clin Oncol 38: 2020 (suppl; abstr 3624)

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
TP53 mutant	ovarian carcinoma	predicted - sensitive	Adavosertib	Case Reports/Case Series	Actionable	In a Phase I trial, Adavosertib (MK-1775) treatment resulted in a partial response (PR) in 17% (6/35) of patients with advanced solid tumors, 4 of the patients achieved PR had ovarian carcinoma (OVC), and TP53 mutations were identified in 2 of the OVC patients with biopsies available for genomic analysis (J Clin Oncol 38: 2020 (suppl; abstr 3624); NCT01748825).	detail...
TP53 mutant	endometrial carcinoma	predicted - sensitive	Adavosertib	Case Reports/Case Series	Actionable	In a Phase I trial, Adavosertib (MK-1775) treatment resulted in a partial response (PR) in 17% (6/35) of patients with advanced solid tumors, 2 of the patients achieved PR had endometrial carcinoma (EC), and TP53 mutations were identified in 1 of the EC patients with biopsy available for genomic analysis (J Clin Oncol 38: 2020 (suppl; abstr 3624); NCT01748825).	detail...
TP53 mutant	Advanced Solid Tumor	predicted - sensitive	Adavosertib	Phase I	Actionable	In a Phase I trial, Adavosertib (MK-1775) treatment resulted in a prtial response in 3 and progressive disease in 2 of 6 patients with advanced solid tumors harboring TP53 mutations (J Clin Oncol 38: 2020 (suppl; abstr 3624); NCT01748825).	detail...